OverviewSuggest Edit

Kadmon is a biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology, and genetic diseases. 

TypePublic
Founded2010
HQNew York, NY, US
Websitekadmon.com
Employee Ratings2.3

Latest Updates

Employees (est.) (Dec 2019)115
Revenue (FY, 2020)$8.3 M(+63%)
Share Price (Apr 2021)$3.8(+4%)
Cybersecurity ratingCMore

Key People/Management at Kadmon

Tasos G. Konidaris

Tasos G. Konidaris

Chairman of the Board
Harlan W. Waksal

Harlan W. Waksal

President, Chief Executive Officer and Director
Steven Meehan

Steven Meehan

Executive Vice President, Chief Financial Officer
Simon Cooper

Simon Cooper

Chief Medical Officer
Eugene Bauer

Eugene Bauer

Director
Gregory S. Moss

Gregory S. Moss

Executive Vice President, General Counsel and Corporate Secretary, Chief Compliance Officer
Show more

Kadmon Office Locations

Kadmon has offices in New York, Cambridge and Warrendale
New York, NY, US (HQ)
450 E 29th St
Cambridge, MA, US
55 Cambridge Pkwy #300e
Warrendale, PA, US
119 Commonwealth Dr
Show all (3)

Kadmon Financials and Metrics

Kadmon Revenue

Kadmon's revenue was reported to be $8.29 m in FY, 2020
USD

Revenue (FY, 2020)

8.3m

Net income (FY, 2020)

(108.9m)

EBIT (FY, 2020)

(102.3m)

Market capitalization (20-Apr-2021)

658.1m

Closing stock price (20-Apr-2021)

3.8

Cash (31-Dec-2020)

74.4m

EV

605.1m
Kadmon's current market capitalization is $658.1 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

26.1m12.3m1.4m5.1m8.3m

Cost of goods sold

682.0k

Gross profit

714.0k

Gross profit Margin, %

51%
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

6.4m5.7m5.6m3.0m2.3m433.0k359.0k372.0k241.0k226.0k226.0k6.7m448.0k490.0k

Cost of goods sold

880.0k880.0k346.0k201.0k79.0k45.0k

Gross profit

5.5m4.8m87.0k158.0k293.0k181.0k

Gross profit Margin, %

86%85%20%44%79%80%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

36.1m67.5m94.7m139.6m74.4m

Accounts Receivable

655.0k325.0k1.7m954.0k695.0k

Prepaid Expenses

978.0k1.1m1.6m1.4m2.1m

Inventories

2.0m201.0k925.0k640.0k102.0k
USDQ2, 2016

Financial Leverage

1 x
Show all financial metrics

Kadmon Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

Kadmon Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Kadmon Online and Social Media Presence

Embed Graph

Kadmon News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kadmon Holdings, Inc., of Class Action Lawsuit and Upcoming Deadline - KDMN

NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its officers. The class action, filed in the United States District Court for the Eastern...

KDMN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kadmon Holdings, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its officers, on behalf of shareholders wh…

Pomerantz Law Firm Announces the Filing of a Class Action against Kadmon Holdings, Inc., and Certain Officers - KDMN

NEW YORK, April 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its officers. The class action, filed in the United States District Court for the Eastern...

Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial Results

NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2019.

Kadmon biopharma shares rise on interim trial results

Shares of Kadmon Holdings are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary endpoint in a trial. Chronic graft-versus-host disease is a rare condition that can occur after a transplant. …

Kadmon Announces Appointment of Steven Meehan as CFO

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of Steven Meehan as Executive Vice President, Chief Financial Officer. Mr. Meehan, who has served as a member of the Board of Directors at Kadmon since 2017, has over 25 years of financia…
Show more

Kadmon Frequently Asked Questions

  • When was Kadmon founded?

    Kadmon was founded in 2010.

  • Who are Kadmon key executives?

    Kadmon's key executives are Tasos G. Konidaris, Harlan W. Waksal and Steven Meehan.

  • How many employees does Kadmon have?

    Kadmon has 115 employees.

  • What is Kadmon revenue?

    Latest Kadmon annual revenue is $8.3 m.

  • What is Kadmon revenue per employee?

    Latest Kadmon revenue per employee is $72.1 k.

  • Who are Kadmon competitors?

    Competitors of Kadmon include Reata Pharmaceuticals, Pliant Therapeutics and Cipla.

  • Where is Kadmon headquarters?

    Kadmon headquarters is located at 450 E 29th St, New York.

  • Where are Kadmon offices?

    Kadmon has offices in New York, Cambridge and Warrendale.

  • How many offices does Kadmon have?

    Kadmon has 3 offices.